PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma
Jiaxin Cao(Sun Yat-sen University), Hongyun Zhao(Sun Yat-sen University)
Cited by 4
Related Papers
Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth
|Nature Metabolism|2022|155
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
|Nature Medicine|2025|76
Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors
|JAMA Oncology|2022|69
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation
|Cellular and Molecular Immunology|2023|65
A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
|Cancer Communications|2020|54